JNJ - Johnson & Johnson

NYSE - NYSE Delayed Price. Currency in USD
138.85
+0.01 (+0.01%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close138.84
Open139.50
Bid138.72 x 800
Ask139.26 x 800
Day's Range138.56 - 139.50
52 Week Range118.62 - 148.99
Volume5,473,499
Avg. Volume6,190,411
Market Cap368.655B
Beta (3Y Monthly)0.68
PE Ratio (TTM)25.73
EPS (TTM)5.40
Earnings DateJul 16, 2019
Forward Dividend & Yield3.80 (2.69%)
Ex-Dividend Date2019-05-24
1y Target Est148.12
  • Associated Press3 hours ago

    Teva settles with Oklahoma for $85 million in opioid case

    NORMAN, Okla. (AP) — One of the drugmakers named in Oklahoma's lawsuit over the opioid crisis has agreed to a settlement in which it will pay the state $85 million.

  • Reuters3 hours ago

    Teva Pharm to pay Oklahoma $85 mln to settle opioid claims

    BOSTON/JERUSALEM, May 26 (Reuters) - Teva Pharmaceutical Industries said on Sunday it had agreed an $85 million settlement with the state of Oklahoma days before the company was set to face trial over allegations that it and other drugmakers helped to fuel the U.S. opioid epidemic. Teva, the world's largest generic drugmaker, said the settlement "does not establish any wrongdoing on the part of the company" and denied contributing to opioid abuse in Oklahoma. Claims against Teva focused on the branded opioid products Actiq and Fentora as well as generic painkillers it produced.

  • Financial Times12 hours ago

    Teva to pay $85m to Oklahoma over opioid case

    Teva Pharmaceuticals will pay $85m to Oklahoma to settle claims that it played a part in fuelling the state’s opioid crisis. Teva and the state government finalised the deal ahead of a trial, which was scheduled to begin on Tuesday. The proceedings will continue against defendant Johnson & Johnson, the world’s largest drugmaker, which has not settled with the state.

  • Bloomberg2 days ago

    Drug Makers' Opioid Liability Tied to Untested Legal Theory

    Oklahoma is the first to go to trial with a case relying on nuisance laws normally invoked for minor property disputes involving things such as loud noises or bright lights. “It’s the first time this theory has actually gotten to trial in pharmaceutical litigation, so everybody will be watching to see if it works,” said Richard C. Ausness, a University of Kentucky law professor who monitors opioid litigation. Oklahoma Attorney General Mike Hunter claims J&J and Teva are liable for at least $10 billion in damages from the state’s two-decade surge in opioid addiction.

  • Pharma Stock Roundup: MRK's Cancer Biotech Buyout, ABBV, LLY's Pipeline Updates
    Zacks2 days ago

    Pharma Stock Roundup: MRK's Cancer Biotech Buyout, ABBV, LLY's Pipeline Updates

    Key highlights of the week include Merck's (MRK) offer to buy private cancer biotech and AbbVie (ABBV) and Lilly's (LLY) updates from clinical studies.

  • Dow 30 Stock Roundup: Home Depot Earnings Impress, Merck to Buy Peloton Therapeutics
    Zacks2 days ago

    Dow 30 Stock Roundup: Home Depot Earnings Impress, Merck to Buy Peloton Therapeutics

    The index suffered a difficult week as investors braced for a protracted U.S.-China trade war.

  • Better Buy: Johnson & Johnson vs. GlaxoSmithKline
    Motley Fool3 days ago

    Better Buy: Johnson & Johnson vs. GlaxoSmithKline

    Which of these top dividend-paying pharma stocks is the better buy right now?

  • J&J's Invokana sNDA Gets Priority Review Status From FDA
    Zacks3 days ago

    J&J's Invokana sNDA Gets Priority Review Status From FDA

    FDA grants priority review to J&J's (JNJ) Invokana sNDA for the treatment of chronic kidney disease in patients with type II diabetes

  • Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
    Zacks4 days ago

    Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know

    Johnson & Johnson (JNJ) closed the most recent trading day at $138.76, moving +0.46% from the previous trading session.

  • Reuters4 days ago

    Congo wants more use of Merck vaccine rather than J&J newcomer - minister

    Democratic Republic of Congo called on Wednesday for Merck's experimental Ebola vaccine to be fully licensed to facilitate its use in the Ebola-hit country, while saying Johnson & Johnson's rival drug would complicate matters. Both vaccines are experimental drugs that can be used under strictly controlled research protocols but Merck's has been used throughout the outbreak and has proven highly effective, the World Health Organization (WHO) says. Congolese Health Minister Oly Ilunga Kalenga told reporters in Geneva that the government would roll out a "geographic ring" vaccination strategy in the coming days.

  • Benzinga4 days ago

    The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 21) Array Biopharma Inc (NASDAQ: ARRY ) (announced positive ...

  • West Chester company to eliminate 76 jobs
    American City Business Journals5 days ago

    West Chester company to eliminate 76 jobs

    Medical Device company DePuy Synthes is eliminating 76 jobs in Chester County. A Worker Adjustment and Retraining Notification Act notice the orthopedic and neurosurgery products developer filed last week with the Pennsylvania Department of Labor and Industry stated its DePuy Synthes Sales Inc. unit will be eliminating its extremities sales organization in West Chester. Asked about the job reduction, DePuy Synthes issued a statment that read: "DePuy Synthes recently made a strategic decision to move away from a dedicated extremities sales force as part of an ongoing assessment of resource utilization and optimization, resulting in an overall reduction in positions.

  • The Zacks Analyst Blog Highlights: Johnson & Johnson, Apple, Goldman Sachs, IBM and Netflix
    Zacks5 days ago

    The Zacks Analyst Blog Highlights: Johnson & Johnson, Apple, Goldman Sachs, IBM and Netflix

    The Zacks Analyst Blog Highlights: Johnson & Johnson, Apple, Goldman Sachs, IBM and Netflix

  • 2 Stocks to be Wary Of (And One Defensive Play)
    TipRanks5 days ago

    2 Stocks to be Wary Of (And One Defensive Play)

    The trade war with China has reignited, and while the tech companies may be getting the headlines, export-oriented industrials have also felt immediate effects. China is an important market for heavy construction and agricultural equipment, and the imposition of protective tariffs has made a mark on the import-export trade.We’ll dive into TipRanks’ analyst database to look at two major industrial companies feeling the pain from China, as well as one strong defensive play to minimize the hurt on your portfolio. Caterpillar, Inc. (CAT – Research Report)Despite beating expectations in the China market earlier this year, Caterpillar now says it expects full-year China-sales results to come in flat at best. This is a serious setback, as Caterpillar makes 10% of its global sales to China. Combined with a drop in operating margin – reported at 18.5% last month, down from 19.7% one year ago – the company is facing a serious headwind in East Asia.Quoted in Canada’s Globe and Mail newspaper, five-star analyst Stephen Volkmann (Track Record & Ratings) noted both points, saying, “Caterpillar has most exposure to China in their construction industry business and that business was just a bit disappointing on revenue and margins.”Caterpillar stock has had a difficult time gaining traction in recent years, as its share price peaked in January 2018 and has been on an uneven downward slope since then. With the end of Q2 2019, the company moved to placate shareholders, by boosting the dividend 20% to $1.03 per share ($4.12 annualized), which increased the yield to a respectable 3.37%. Shares gained $4 in the next session but are down $17 since.While CAT is facing headwinds, the outlook is not entirely gloomy. Oppenheimer’s Noah Kaye (Track Record & Ratings) set a ‘Hold’ on the stock, but his comments acknowledge that the company has extensive resources: “We got much of what we were looking for from CAT’s Investor Day last week. The company provided an updated view on its structurally improved cross-cycle margin and cash flow metrics… We believe CAT’s O&E model has successfully enabled the company to deliver stronger cash generation peak-to-trough and supported its strong balance sheet, enabling a more shareholder-friendly approach to capital allocation.”Overall, CAT retains a ‘Moderate Buy’ from the analyst consensus, including 9 buy, 3 hold, and 2 sell reviews. Shares sell for $122 as of May 20, and the average price target of $150 suggests a 22% upside potential.View CAT Price Target & Analyst Rating Detail Deere & Co. (DE – Research Report)Nothing runs like a Deere, but investors ran away from Deere shares after the May 17 Q2 earnings report. The manufacturer of agricultural equipment (from backyard riding mowers to giant agribusiness harvester combines, plus everything in between) missed the EPS forecast by 2%, reporting $3.52 against the expected $3.61. Despite the earnings miss, net equipment sales revenues came in just above the $10.12 billion expectation, at $10.3 billion.According to the company, however, investors should not expect to keep seeing revenue beats this year. Deere lowered guidance on 2019 net income from $3.6 billion to $3.3 billion. Company CEO Sam Allen said of the lower guidance, “Although the long-term fundamentals for our businesses remain favorable, softening conditions in the agricultural sector have led Deere to adopt a more cautious financial outlook for the year. The lower forecast is partly a result of actions we are taking to prudently manage field inventories, which will cause production levels to be below retail sales in the second half of the year.”DE shares dropped 7.5% after the earnings report.Wall Street’s analysts have also seen the weakness in DE, even those setting ‘buy’ ratings on the stock. From RBC Capital, Seth Weber (Track Record & Ratings) says of the lowered income guidance, “…the revision is not surprising in light of the U.S.-China trade tensions and bad weather.” He lowered his price target by 10%, to $175.Stanley Elliot (Track Record & Ratings), of Stifel, also notes the softness in the agribusiness sector. He says the lowered income projection is driven by “a cocktail of negative developments in terms of trade, late plantings and swine flu.” His price target, $171, suggests a 26% upside for the stock.Deere holds a ‘Moderate Buy’ rating on the analyst consensus, based on 5 buy, 4 hold, and 1 sell rating given in the past three months. The $155 average price target that indicates a 14% upside potential from the current share price of $135.View DE Price Target & Analyst Rating Detail Johnson & Johnson (JNJ – Research Report)Consumer health care companies, emphasizing the everyday items that everyone needs no matter the state of the economy, are among the stocks usually seen as ‘recession proof.’ This doesn’t mean that they won’t drop when the market drops; rather, it means that they’ll experience less volatility. You can expect these defensive stocks to outperform when the major indexes fall or make slow gains, but they’ll also tend to lag a bit when the markets see a sharp rise.Johnson & Johnson is a classic case. JNJ released its Q1 earnings, missing the EPS by 2 cents, on April 16. Since then, the stock has slipped, risen, and slipped again, and is flat overall. On a longer-term view, JNJ is up 7.3% year-to-date and 11.4% over the past 12 months. The S&P 500, for April, is down over 2%, and in the last 12 months is only up 4%.Outperforming market slips is not JNJ’s only defensive attribute. The stock pays out a regular dividend, currently 95 cents per quarter for a 2.75% annual yield. The company has made a policy of steady, if modest, dividend increases, dating back to the early 1990s.The analysts, of course, have taken note of JNJ’s dependability in delivering profits and rewarding shareholders. Raymond James analyst Jayson Bedford (Track Record & Ratings), just after the earnings report, raised his price target to $147 (for a 6% upside), and said, “Growth was still much better than expected, which gives us more confidence in our estimates.”More recently, five-start analyst Joanne Wuensch (Track Record & Ratings) of BMO Capital, noted JNJ’s attraction in a down market. In her note on the stock, she said, “J&J's discipline to acquire and divest assets in its health care portfolio, its pristine balance sheet and its high dividend yield make the stock a strong defensive choice.” Her price target, $157, suggests an upside potential of 13%.JNJ maintains a ‘Moderate Buy’ analyst consensus rating, based on 6 buys and 5 holds given in the past three months. Shares sell for $138; the average price target of $148 indicates a modest upside potential of 7%.View JNJ Price Target & Analyst Rating Detail Enjoy Research Reports on the Stocks in this Article:Caterpillar, Inc. (CAT) Research ReportDeere & Co. (DE) Research ReportJohnson & Johnson (JNJ) Research Report

  • Zacks Small Cap Research6 days ago

    ARWR: ARO-AAT Ph 2/3 Detailed, Could Serve as FDA Pivotal Study. Continued Broad-Based Pipeline Progress

    This includes presentations at the EASL International Liver Congress in April from preclinical long-term data from the previous-generation AAT as well as interim results of JNJ-3989 (ARO-HBV) among 40 patients at 24+ weeks follow-up in their ongoing Phase 1/2 study. The JNJ-3989 Phase 1/2 study (chronic hepatitis B) continues and was recently expanded to include a triple combination cohort (cohort 12), which along with JNJ-3989, will include additional undisclosed agents chosen by Janssen. Management indicated that this triple combination cohort could generate data relatively quickly – which will be one of several near-term development-related announcements that we anticipate.

  • Top Analyst Reports for Johnson & Johnson, Apple & Goldman Sachs
    Zacks6 days ago

    Top Analyst Reports for Johnson & Johnson, Apple & Goldman Sachs

    Top Analyst Reports for Johnson & Johnson, Apple & Goldman Sachs

  • Drugmakers’ lobbying spending at 10-year high as Washington targets soaring prices
    MarketWatch6 days ago

    Drugmakers’ lobbying spending at 10-year high as Washington targets soaring prices

    The spending by the industry’s main trade group and seven key drugmakers has climbed to a level not seen in a decade.

  • This is Why Johnson & Johnson (JNJ) is a Great Dividend Stock
    Zacks6 days ago

    This is Why Johnson & Johnson (JNJ) is a Great Dividend Stock

    Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.

  • AbbVie's Brain Cancer Candidate Fails in Phase III Study
    Zacks6 days ago

    AbbVie's Brain Cancer Candidate Fails in Phase III Study

    AbbVie's (ABBV) phase III study on Depatux-M, an investigational candidate for newly diagnosed glioblastoma, fails to show survival benefit in patients receiving Depatux-M.

  • After J&J sale, Cambridge investor sets sights on $175M raise for new medtech VC firm
    American City Business Journals6 days ago

    After J&J sale, Cambridge investor sets sights on $175M raise for new medtech VC firm

    With the launch of his new company, Miraki Innovation, Velis hopes to expand his reach in medtech, founding more companies in healthcare diagnostics, infectious disease and robotics that will follow Auris’ lead.

  • Reuters7 days ago

    Modi’s jobs deficit - J&J’s largest India plant idle three years after completion

    PENJERLA/NEW DELHI, India (Reuters) - It was supposed to be Johnson & Johnson's biggest manufacturing plant in India. It was to eventually employ at least 1,500 people and help bring development to a rural area near Hyderabad in southern India. Two sources familiar with J&J's operations in India and one state government official told Reuters production at the plant, at Penjerla in Telangana state, never began because of a slowing in the growth in demand for the products.

  • Reuters7 days ago

    Modi’s jobs deficit: J&J’s largest India plant idle 3 years after completion

    PENJERLA/NEW DELHI, India May 19 (Reuters) - It was supposed to be Johnson & Johnson's biggest manufacturing plant in India. It was to eventually employ at least 1,500 people and help bring development to a rural area near Hyderabad in southern India. Two sources familiar with J&J's operations in India and one state government official told Reuters production at the plant, at Penjerla in Telangana state, never began because of a slowing in the growth in demand for the products.

  • Benzinga8 days ago

    Bulls And Bears Of The Week: Apple, Chevron, FedEx, Uber And More

    Benzinga has examined prospects for many investor favorite stocks over the past week. Bearish calls included biotechs and a recent IPO. Furthermore, investors also saw mixed economic numbers, as well as positive surprises in quarterly reports and initial public offerings, bad news for a market darling from the Supreme Court, and fresh news for whale watchers.

  • Health care recovery? 3 trades
    CNBC Videos3 days ago

    Health care recovery? 3 trades

    The "Fast Money" traders talk health care as the sector seems to be going through a recovery.

  • The View from New Brunswick: Johnson & Johnson CEO Alex Gorsky at Healthy Returns
    CNBC Videos3 days ago

    The View from New Brunswick: Johnson & Johnson CEO Alex Gorsky at Healthy Returns

    The View from New Brunswick Johnson & Johnson is continuously pioneering new techniques and concepts for a brighter, healthier future. What the landscape looks like from atop one of the world's biggest and most admired health care companies. CNBC's Meg Tirrell concludes the day with J&J chairman and CEO Alex Gorsky.